These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36253453)

  • 1. IgG-cleavage protein allows therapeutic AAV gene delivery in passively immunized MPS IIIA mice.
    Bobo TA; Samowitz PN; Robinson MI; Montes LI; Forsberg LJ; Feng R; Nicely NI; Fu H
    Gene Ther; 2023 Apr; 30(3-4):377-385. PubMed ID: 36253453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Threshold for Pre-existing Antibody Levels Limiting Transduction Efficiency of Systemic rAAV9 Gene Delivery: Relevance for Translation.
    Meadows AS; Pineda RJ; Goodchild L; Bobo TA; Fu H
    Mol Ther Methods Clin Dev; 2019 Jun; 13():453-462. PubMed ID: 31193101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy.
    Fu H; Meadows AS; Pineda RJ; Kunkler KL; Truxal KV; McBride KL; Flanigan KM; McCarty DM
    Hum Gene Ther Clin Dev; 2017 Dec; 28(4):187-196. PubMed ID: 29064732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies.
    Ros-Gañán I; Hommel M; Trigueros-Motos L; Tamarit B; Rodríguez-García E; Salas D; Pérez G; Douar A; Combal JP; Benichou B; Ferrer V; González-Aseguinolaza G
    Clin Transl Immunology; 2022; 11(2):e1375. PubMed ID: 35228870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IdeS: a bacterial proteolytic enzyme with therapeutic potential.
    Johansson BP; Shannon O; Björck L
    PLoS One; 2008 Feb; 3(2):e1692. PubMed ID: 18301769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase.
    Tradtrantip L; Asavapanumas N; Verkman AS
    Mol Pharmacol; 2013 Jun; 83(6):1268-75. PubMed ID: 23571414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies.
    Leborgne C; Barbon E; Alexander JM; Hanby H; Delignat S; Cohen DM; Collaud F; Muraleetharan S; Lupo D; Silverberg J; Huang K; van Wittengerghe L; Marolleau B; Miranda A; Fabiano A; Daventure V; Beck H; Anguela XM; Ronzitti G; Armour SM; Lacroix-Desmazes S; Mingozzi F
    Nat Med; 2020 Jul; 26(7):1096-1101. PubMed ID: 32483358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes.
    Yang R; Otten MA; Hellmark T; Collin M; Björck L; Zhao MH; Daha MR; Segelmark M
    Nephrol Dial Transplant; 2010 Aug; 25(8):2479-86. PubMed ID: 20219834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking of experimental arthritis by cleavage of IgG antibodies in vivo.
    Nandakumar KS; Johansson BP; Björck L; Holmdahl R
    Arthritis Rheum; 2007 Oct; 56(10):3253-60. PubMed ID: 17907170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgG-degrading enzyme of Streptococcus pyogenes (IdeS) prevents disease progression and facilitates improvement in a rabbit model of Guillain-Barré syndrome.
    Wang Y; Shi Q; Lv H; Hu M; Wang W; Wang Q; Qiao B; Zhang G; Lv Z; Kjellman C; Järnum S; Winstedt L; Zhang Y; Wen J; Hao Y; Yuki N
    Exp Neurol; 2017 May; 291():134-140. PubMed ID: 28214515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease.
    Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M
    Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin cleavage by the streptococcal cysteine protease IdeS can be detected using protein G capture and mass spectrometry.
    Hess JL; Porsch EA; Shertz CA; Boyle MD
    J Microbiol Methods; 2007 Aug; 70(2):284-91. PubMed ID: 17543400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia.
    Kizlik-Masson C; Deveuve Q; Zhou Y; Vayne C; Thibault G; McKenzie SE; Pouplard C; Loyau S; Gruel Y; Rollin J
    Blood; 2019 May; 133(22):2427-2435. PubMed ID: 30917957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement Vector.
    Bobo TA; Samowitz PN; Robinson MI; Fu H
    Mol Ther Methods Clin Dev; 2020 Dec; 19():474-485. PubMed ID: 33313335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
    MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Streptococcal IdeS: therapeutic potential for Guillain-Barré syndrome.
    Takahashi R; Yuki N
    Sci Rep; 2015 Jul; 5():10809. PubMed ID: 26194472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice.
    Duncan FJ; Naughton BJ; Zaraspe K; Murrey DA; Meadows AS; Clark KR; Newsom DE; White P; Fu H; McCarty DM
    Mol Ther; 2015 Apr; 23(4):638-47. PubMed ID: 25592334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The streptococcal protease IdeS modulates bacterial IgGFc binding and generates 1/2Fc fragments with the ability to prime polymorphonuclear leucocytes.
    Söderberg JJ; von Pawel-Rammingen U
    Mol Immunol; 2008 Jul; 45(12):3347-53. PubMed ID: 18533265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
    King B; Hassiotis S; Rozaklis T; Beard H; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM
    J Neurochem; 2016 May; 137(3):409-22. PubMed ID: 26762778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid IgG heavy chain cleavage by the streptococcal IgG endopeptidase IdeS is mediated by IdeS monomers and is not due to enzyme dimerization.
    Vindebro R; Spoerry C; von Pawel-Rammingen U
    FEBS Lett; 2013 Jun; 587(12):1818-22. PubMed ID: 23665032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.